☆ 4.7 Article

Impact of Helicobacter pylori infection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study

S. Y. Rha et al.

ANNALS OF ONCOLOGY (2023)

添加到收藏夹

Review Gastroenterology & Hepatology

Gut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy

Despoina Chrysostomou et al.

Summary: Accumulating evidence supports the important role of the gut microbiome in cancer development and progression, as well as its influence on the efficacy and toxicity of cancer treatments. The microbiome is now being utilized to develop personalized therapeutic approaches in cancer treatment. However, the development of a new model that incorporates gut microbial cometabolism of drugs is necessary for the successful translation of the microbiome into next-generation oncologic treatments. The objective of this review is to outline the current knowledge of oncologic pharmacomicrobiomics and propose innovative approaches to modulate the gut microbiome for improved therapy efficacy and reduced toxic effects.

GASTROENTEROLOGY (2023)

添加到收藏夹

Article Oncology

Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors

Mridula Krishnan et al.

Summary: Clinical trials for immune checkpoint inhibitors (ICI) have mainly focused on patients with good performance status. However, this study found that ICI treatment in patients with poor performance status had worse outcomes, with lower overall survival and response rates. Further prospective trials are needed to define the role and effectiveness of ICI in patients with poor performance status.

JCO ONCOLOGY PRACTICE (2022)

添加到收藏夹

Article Oncology

Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08)

Yoshikazu Takahashi et al.

Summary: This multicenter prospective observational study evaluated the efficacy of nivolumab treatment for advanced gastric cancer, showing comparable survival outcomes with previous clinical trials and revealing the frequency and prognosis of patients with hyperprogressive disease (HPD).

GASTRIC CANCER (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies

Paul Oster et al.

Summary: This study revealed that Helicobacter pylori infection may reduce the efficacy of cancer immunotherapies, as demonstrated in mouse models and human clinical studies.

GUT (2022)

添加到收藏夹

Article Oncology

Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors

Marion Tonneau et al.

Summary: The microbiome is considered a hallmark of cancer, and strategies to modify the gut microbiota for improved immune checkpoint inhibitor (ICI) activity are being investigated. In this study, it was found that Helicobacter pylori (H. pylori) positivity was associated with a negative prognosis in patients receiving ICI treatment for advanced melanoma. However, the impact of H. pylori on outcomes seemed to be independent of fecal microbiome composition.

ONCOIMMUNOLOGY (2022)

添加到收藏夹

Article Oncology

Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors

Hebin Che et al.

Summary: This study reveals that H. pylori infection is associated with the outcome of immunotherapy for advanced gastric cancer patients. Patients who are H. pylori positive have a higher risk of nonclinical response to anti-PD-1 antibody and shorter overall survival and progression-free survival. Further multicenter, large sample, and prospective clinical studies are needed to verify this association.

BMC CANCER (2022)

添加到收藏夹

Article Oncology

Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma

Krisztian Homicsko et al.

Summary: This retrospective analysis examined the impact of proton pump inhibitors (PPIs) on the efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma. The results showed insufficient evidence to support a meaningful association between PPI use and ICI efficacy.

CANCERS (2022)

添加到收藏夹

Article Oncology

Helicobacter pylori infection as a potential favorable factor for immune checkpoint inhibitor therapy for gastric cancer

Ming-jun Zhang et al.

Summary: The study suggests that positive H. pylori status may be a beneficial prognostic factor for ICI therapy in GC patients, with superior outcomes observed in Asian patients compared to North American and European patients. Therefore, emphasizing H. pylori status in ongoing or forthcoming ICI therapy trials could maximize treatment benefits for patients with advanced GC. Further research is needed to better understand the mechanisms of inflammation and cancer progression.

INVESTIGATIONAL NEW DRUGS (2021)

添加到收藏夹

Article Oncology

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

Alessio Cortellini et al.

Summary: The study reveals the negative impact of antibiotics (ATB) on pembrolizumab monotherapy outcomes in NSCLC, while corticosteroids and proton pump inhibitors (PPIs) may worsen baseline performance status. These findings highlight the underlying immune-modulatory effects of these concomitant medications.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Medicine, General & Internal

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian et al.

Summary: Nivolumab plus chemotherapy showed superior overall survival and progression-free survival compared to chemotherapy alone in previously untreated patients with advanced gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma, indicating it as a new standard first-line treatment option with acceptable safety profile.

LANCET (2021)

添加到收藏夹

Article Oncology

Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer

Bao-Dong Qin et al.

Summary: The study evaluated the impact of concomitant PPI use on the efficacy of ICIs in advanced cancer patients, finding that PPI use was associated with reduced PFS and OS.

ONCOIMMUNOLOGY (2021)

添加到收藏夹

Article Oncology

Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with checkpoint inhibitors

Ali Raza Khaki et al.

CANCER (2020)

添加到收藏夹

Review Medicine, General & Internal

Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis

Fausto Petrelli et al.

JOURNAL OF CLINICAL MEDICINE (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

The role of gut microbiota in cancer treatment: friend or foe?

Wing Yin Cheng et al.

GUT (2020)

添加到收藏夹

Article Oncology

The effect of proton pump inhibitor uses on outcomes for cancer patients treated with immune checkpoint inhibitors: a meta-analysis

Chao Li et al.

ANNALS OF TRANSLATIONAL MEDICINE (2020)

添加到收藏夹

Article Microbiology

Increased Programmed Death-Ligand 1 is an Early Epithelial Cell Response to Helicobacter pylori Infection

Loryn Holokai et al.

PLOS PATHOGENS (2019)

添加到收藏夹

Review Oncology

The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?

A. Elkrief et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Microbiology

Helicobacter pylori evasion strategies of the host innate and adaptive immune responses to survive and develop gastrointestinal diseases

Ahmad Karkhah et al.

MICROBIOLOGICAL RESEARCH (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients

V. Gopalakrishnan et al.

SCIENCE (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Bertrand Routy et al.

SCIENCE (2018)

添加到收藏夹

Article Immunology

The role of T helper 1-cell response in Helicobacter pylori-infection

Nader Bagheri et al.

MICROBIAL PATHOGENESIS (2018)

添加到收藏夹

Article Medicine, General & Internal

Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer

Il Ju Choi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Oncology

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial

Charles S. Fuchs et al.

JAMA ONCOLOGY (2018)

添加到收藏夹

Review Biochemistry & Molecular Biology

Spotlight on protein N-terminal acetylation

Rasmus Ree et al.

EXPERIMENTAL AND MOLECULAR MEDICINE (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

Marie Vetizou et al.

SCIENCE (2015)

添加到收藏夹

Article Oncology

Global burden of gastric cancer attributable to Helicobacter pylori

Martyn Plummer et al.

INTERNATIONAL JOURNAL OF CANCER (2015)

添加到收藏夹

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.